Navigation Links
Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
Date:7/6/2010

MENLO PARK, Calif., July 6 /PRNewswire/ -- Crux Biomedical®Inc. announced today that it has successfully enrolled the first patient in its Retrieve 2 pivotal U.S. IDE trial. The trial will evaluate the safety and efficacy of Crux's new Vena Cava Filter (VCF). The Crux VCF is a retrievable, implantable filter which is designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). It is the first VCF to be developed that is bidirectional and thus permits insertion or retrieval from either the femoral or jugular veins.

The implant was performed by Jon Hupp, a vascular surgeon at Anne Arundel Medical Center, located in Annapolis, Maryland. "Current retrievable filters either require short term removal or seem to have an unacceptable frequency of migration or fracture issues. Hopefully, the Crux filter will improve on this situation. There are a large number of patients who could benefit from such a device," Dr. Hupp explained. Crux's Retrieve 2 study is being conducted at 18 sites in the United States.

Vena cava filters were originally designed as a permanent implant only. Subsequent design improvements have provided physicians with the option to retrieve the filter once a patient is no longer at risk of a PE. Presently in the United States, over 50% of vena cava filters implanted are designed for retrieval at a later date. However, currently cleared vena cava filters are associated with a variety of complications. These complications present challenges to the physician when attempting to retrieve the device. The Crux VCF design will prevent filter tilt and associated challenges in retrieval. "Physicians are very enthusiastic with our bidirectional design and the additional choices that it will provide in delivery and retrieval of the implant," stated Mel Schatz, CEO of Crux Biomedical.

Vena cava filters were first introduced in the 1960s and have become an important tool to reduce the occurrence of a PE. There are an estimated 200,000 deaths per year attributed to PE in the United States. The CDC and the American Public Health Association have indicated that the deaths due to PE exceed the combined mortality per annum in the U.S. attributed to breast cancer, AIDS and traffic accidents.  

Crux Biomedical was founded in 2004 by Dr. Thomas Fogarty and specializes in minimally invasive medical implants. It is headquartered in Menlo Park, California and is funded by Alloy Ventures and Emergent Medical Partners.


'/>"/>
SOURCE Crux Biomedical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Drexel Biomedical Researchers Develop Device to Predict Diabetic Wound Healing
2. West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund
3. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
4. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
5. Biomedical Advanced Research and Development Authority (BARDA) Project for Radiation Exposure Research Awarded to SRI International
6. Volcano Corporation Completes Acquisition of Lumen Biomedicals Xtract(TM) Thrombus Aspiration Catheter
7. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
8. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
9. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
10. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
11. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... 2017  A new tight-tolerance microextrusion medical tubing ... materials, is being launched by Natvar, a Tekni-Plex ... in recent years to service a wide variety ... More expensive materials such as glass and fluoropolymers ... to their ability to consistently hold tolerances. This ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/2/2017)... NEW YORK and LONDON ... distributor of market intelligence, MarketResearch.com is pleased to announce ... Consulting AB that allows for the marketing and ... market analyses through the MarketResearch.com website. The ... access to complete product descriptions and tables of contents ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with ... new study from the Osteoarthritis Initiative shows that certain people who experience ... this in advance may give doctors the opportunity to treat patients before the problem ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from ... May 30th and 31st at The Four Seasons Hotel Boston. , The ... life sciences, offering exclusive access to key decision makers who influence deal making ...
(Date:5/26/2017)... Clara, Calif. (PRWEB) , ... May 26, 2017 ... ... announces the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware ... provides a consistent, browser-based interface for diagnostic device operations. With this platform, initializing ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):